SNY Stock Recent News

SNY LATEST HEADLINES

SNY Stock News Image - zacks.com

Sanofi wins EMA's orphan drug status for rilzabrutinib to treat IgG4-RD, a chronic, immune-mediated rare disease.

zacks.com 2025 Aug 15
SNY Stock News Image - globenewswire.com

Sanofi's rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025 Additional orphan designation underscores Sanofi commitment to advancing new medicines in immune-mediated rare diseases Paris, August 14, 2025. The European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible covalent Bruton's tyrosine kinase (BTK) inhibitor, for IgG4-related disease (IgG4-RD).

globenewswire.com 2025 Aug 14
SNY Stock News Image - reuters.com

Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French pharmaceuticals firm and its partner Regeneron Pharmaceuticals, in China due to limited availability.

reuters.com 2025 Aug 12
SNY Stock News Image - seekingalpha.com

Sanofi's strategic pivot to immunology and rare diseases, plus AI-driven R&D, targets higher margins and sustainable long-term growth. Blockbuster drugs like Dupixent, Altuviiio, and Beyfortus, alongside a robust late-stage pipeline, underpin future revenue potential. Risks include heavy Dupixent reliance, looming patent expirations, US policy uncertainty, and ongoing legal disputes with Regeneron.

seekingalpha.com 2025 Aug 07
SNY Stock News Image - globenewswire.com

Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. (“Vigil”).

globenewswire.com 2025 Aug 06
SNY Stock News Image - wsj.com

Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

wsj.com 2025 Aug 01
SNY Stock News Image - businesswire.com

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to develop and commercialize four of Arrowhead's investigational cardiometabolic candidates in Greater China. Under the terms, Sanofi will acquire rights to develop and commercialize investigational plozasiran, Arrowhead's first-in-class RNA interference (RNAi) therap.

businesswire.com 2025 Aug 01
SNY Stock News Image - seekingalpha.com

Sanofi (NASDAQ:SNY ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Brian Foard - Executive VP & Head of Specialty Care François-Xavier Roger - Executive VP & CFO Houman Ashrafian - Executive VP & Head of Research Development Paul Hudson - CEO & Director Roy Papatheodorou - Executive VP & General Counsel Thomas Triomphe - Executive Vice President of Vaccines Thomas Kudsk Larsen - Head of Investor Relations Conference Call Participants Benjamin Jackson - Jefferies LLC, Research Division David Reed Risinger - Leerink Partners LLC, Research Division Florent Cespedes - Sanford C. Bernstein & Co., LLC.

seekingalpha.com 2025 Jul 31
SNY Stock News Image - reuters.com

U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House said on Thursday.

reuters.com 2025 Jul 31
SNY Stock News Image - cnbc.com

President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a controversial policy that aims to slash drug costs by tying the prices of some medicine in the U.S. to the significantly lower ones abroad.

cnbc.com 2025 Jul 31
10 of 50